Home » Stocks » HOTH

Hoth Therapeutics, Inc. (HOTH)

Stock Price: $2.47 USD 0.15 (6.47%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $2.41 -0.06 (-2.43%) Jan 27, 7:50 AM
Market Cap 39.31M
Revenue (ttm) n/a
Net Income (ttm) -10.35M
Shares Out 13.43M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.47
Previous Close $2.32
Change ($) 0.15
Change (%) 6.47%
Day's Open 2.35
Day's Range 2.33 - 2.50
Day's Volume 2,218,649
52-Week Range 1.58 - 4.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 6 days ago

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003...

PRNewsWire - 2 weeks ago

NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinica...

PRNewsWire - 3 weeks ago

NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation Licen...

PRNewsWire - 3 weeks ago

NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP mate...

PRNewsWire - 1 month ago

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the...

PRNewsWire - 1 month ago

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearan...

PRNewsWire - 2 months ago

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical dat...

PRNewsWire - 2 months ago

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the no...

PRNewsWire - 3 months ago

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University...

PRNewsWire - 4 months ago

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne ...

PRNewsWire - 4 months ago

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") wi...

PRNewsWire - 4 months ago

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.

PRNewsWire - 4 months ago

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.

PRNewsWire - 5 months ago

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.

PRNewsWire - 5 months ago

NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals...

PRNewsWire - 6 months ago

NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwe...

PRNewsWire - 7 months ago

NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide...

GuruFocus - 7 months ago

Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks ha...

Other stocks mentioned: PDSB
PRNewsWire - 7 months ago

NEW YORK, June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issue...

PRNewsWire - 7 months ago

NEW YORK, May 27, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced un...

PRNewsWire - 8 months ago

NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific A...

PRNewsWire - 8 months ago

NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offe...

PRNewsWire - 8 months ago

NEW YORK, May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virg...

GlobeNewsWire - 10 months ago

Technology Has Been Licensed from Massachusetts General Hospital Technology Has Been Licensed from Massachusetts General Hospital

Zacks Investment Research - 10 months ago

Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.

Benzinga - 10 months ago

Hoth Therapeutics Inc (NASDAQ: HOTH) shares were roaring higher Monday after the biopharma announced its foray into COVID-19 vaccine development, joining a host of companies engaged in researc...

GlobeNewsWire - 1 year ago

ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- It doesn’t take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doe...

GlobeNewsWire - 1 year ago

ORLANDO, Fla., Jan. 14, 2020 (GLOBE NEWSWIRE) -- The headline of our written offering today probably appears a little different from our regular titles. Typically we don’t lead with things t...

GlobeNewsWire - 1 year ago

ORLANDO, Fla., Dec. 23, 2019 (GLOBE NEWSWIRE) -- As the holidays roll into November and December many companies go quietly into the New Year, eschewing news releases or large scale investor ...

About HOTH

Hoth Therapeutics, a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2019
CEO
Robb Knie
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
HOTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Strong Buy